Tirzepatide is a long-acting dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

Detailed results were announced from a phase 3 clinical trial evaluating the use of tirzepatide in adults with heart failure with preserved ejection fraction (HFpEF) and obesity. The multicenter, ...

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers published in JACC, the flagship journal of the American College of Cardiology, ...

The American Heart Association held its annual Scientific Sessions Nov. 16-18 in Chicago, where healthcare organizations and industry leaders presented the latest research on cardiovascular health.

The FDA rejected an application from Astellas seeking to change the prescribing label for its eye drug Izervay to allow less ...

Of the patients who received the treatment, many of who had advanced symptoms of heart failure at the beginning of the study, ...

(HealthDay News) — For patients with obesity and prediabetes, 3 years of tirzepatide yields substantial and sustained weight reduction and a reduced risk for progression to type 2 diabetes, according ...

Four Rochester healthcare organizations are joining together to address the large amount of pharmacy closures throughout the ...

Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...

Since the discovery of statins and the Scandinavian Simvastatin Survival Study (4S) results three decades ago, remarkable advances have been made in the treatment of dyslipidaemia, a major risk factor ...

More than roughly 10-and-a-half hours of ... New Research Shows Relationship Between Heart Shape and Risk of Cardiovascular Disease Nov. 14, 2024 — A new study has revealed that the shape of the ...